gsk share dividend - Search News

GSK launches $2.5 billion buyback, lifts sales target

GSK shares surge around 6% as drugmaker raises sales target and boosts dividends

Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and reported strong financial results for 2024. The stock climbed 5.9% in early trading,

The Financial Times · 2d

GSK launches £2bn buyback on strong HIV and cancer drugs sales

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, including cancer and HIV drugs, sending shares up as much as 6 per cent on Wednesday.

Evening Standard on MSN · 2d

GSK lifts long-term sales targets on new drug pipeline

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js

2don MSN

The GSK share price jumps 6% on positive FY 2024 results. Is it a stock to consider now?

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

2don MSN

FTSE 100 giant GSK eyes more than £40bn in sales by 2031

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer.

GSK PLC (GSK) Q4 2024 Earnings Call Highlights: Strong Specialty Medicines Drive Growth Amid ...

GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.

GSK intends to commence GBP 2B share buyback program

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be ...

GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 Billion

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results